Immune checkpoint inhibitor-based combinatory and alternative strategies for immune treatment of lung cancers
This review summarizes established and emerging ICI-based regimens in lung cancer, mechanisms of resistance relevant to NSCLC and SCLC, biomarker integration for patient selection and monitoring, and future directions to optimize efficacy and safety through combinatory and alternative immunotherapeutic strategies.